Evidence map›Paper›PMID 39816935›Full record

ArticleProstate international2024

Insights from immunomics and metabolomics on the associations between prostatic diseases and coronavirus disease 2019.

Feixiang Yang, Peng Guo, Kun Wang, Xiangyu Zhang, Zhehao Hu, Qiyue Lou, Qintao Ge, Yiding Chen, Chaozhao Liang, Jialin Meng

Abstract read
In one paragraph

Article in Prostate international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Feixiang YangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Peng GuoDepartment of Urology, The Affiliated Jiangyin Hospital of Nantong University, Wuxi, 214400, China.
Kun WangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Xiangyu ZhangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Zhehao HuDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Qiyue LouDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Qintao GeDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Yiding ChenDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Chaozhao LiangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Jialin MengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The causal associations and potential mechanisms between prostatic diseases, the predominant male urological disorders, and the course of COVID-19 remain unclear. Methods: A two-sample Mendelian randomization (MR) analysis was performed to evaluate causal associations between prostate cancer, benign prostatic hyperplasia, and prostatitis and different COVID-19 outcomes (SARS-CoV-2 infection, hospitalized COVID-19, and severe COVID-19). Reverse MR, linkage disequilibrium score regression, and Bayesian colocalization analyses were subsequently performed to strengthen the identified causal relationships. Furthermore, immunome- and metabolome-wide MR analysis was conducted to prioritize COVID-19-associated immune characteristics and metabolites. Two-step MR analysis was performed to evaluate the mediating effects of the immunome and metabolome on the associations between prostatic diseases and COVID-19. Results: Genetically predicted prostatic diseases were not causally associated with severe COVID-19, while prostatitis was suggested to be an independent risk factor for SARS-CoV-2 infection (odds ratio (OR) = 1.11, 95% confidence interval (CI) 1.01 to 1.23; Conclusion: Our study identified the causal relationships of prostatic diseases with COVID-19 and suggested pathways explaining these associations through alterations in the blood immunome and metabolome.

Indexed as

COVID-19ImmunityMendelian randomizationMetabolitesProstatic diseasesProstatitis

Identifiers

PMID39816935
PMCPMC11733763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.